Author/Authors :
Makohusová, Miroslava Department of Chemistry - Faculty of Natural Sciences - University of SS Cyril and Methodius ,Trnava, Slovak Republic , Mrázová, Viera Department of Chemistry - Faculty of Natural Sciences - University of SS Cyril and Methodius ,Trnava, Slovak Republic , Bednárová, Adriána Department of Chemistry - Faculty of Natural Sciences - University of SS Cyril and Methodius ,Trnava, Slovak Republic , Milatová, Eva Department of Internal Medicine - Slovak Medical University - University Hospital, Bratislava, Slovak Republic , Sokol, Jozef Department of Chemistry - Faculty of Natural Sciences - University of SS Cyril and Methodius ,Trnava, Slovak Republic , Pleško, Marek Department of Pediatric Hematology and Oncology - Faculty of Medicine - Comenius University -National Institute of Children’s Diseases, Bratislava, Slovak Republic , Bátorová, Angelika National Hemophilia Center - Department of Hematology and Transfusion Medicine - Faculty of Medicine of the Comenius University - University Hospital, Bratislava, Slovak Republi
Abstract :
A high prevalence of genetic polymorphisms increases sensitivity to warfarin therapy.
In this study, we investigated 47 patients with effective long-term therapy by warfarin wellcontrolled
by monitoring of International Normalised Ratio (INR). All patients were tested for
gene polymorphisms VKORC1, CYP2C9*C2, and CYP2C9*C3, which were used for a dose
calculation employing a program www.WarfarinDosing.org. The main goal was to investigate
whether the warfarin doses determined by INR are in accordance with the doses calculated
according to the pharmacogenetic algorithm. For this purpose, several chemometric tools,
namely principal component analysis, cluster analysis, correlation analysis, correspondence
analysis, Passing-Bablock regression, Bland-Altman method, descriptive statistics, and
ANOVA were used. We also analysed the relationship between the dose of warfarin determined
by INR and several constitutional and genetic factors. Statistically significant association
between clinically optimized warfarin dose and indication for the treatment, age, and
warfarin sensitivity determined by VKORC1, CYP2C9 gene polymorphisms were confirmed.
Finally, we confirmed a good concordance between the INR determined warfarin doses and
pharmacogenetic approach.
Keywords :
Bland-Altman method , Passing-Bablock regression , Gene polymorphisms , Warfarin dose , Pharmacogenetics